526269

- Annual Report for FY 2025-26 submitted. - Total Income: ₹25.52 Cr vs ₹21.52 Cr (▲18.6% YoY) - Net Profit: ₹2.71 Cr vs ₹2.73 Cr (▼0.7% YoY) - EPS: ₹9.04 vs ₹9.08 (▼0.4% YoY) - Final dividend of ₹1.50 (15%) per equity share declared for FY 2025-26. - Annual General Meeting (AGM) to be held on August 06, 2026.

- Standalone Revenue ₹10.23 Cr vs ₹7.23 Cr (▲41.38% YoY) - Standalone EBITDA ₹1.40 Cr vs ₹0.60 Cr (▲131.95% YoY) - Standalone PAT ₹1.10 Cr vs ₹0.61 Cr (▲80.82% YoY) - Standalone EBITDA Margin 13.67% vs 8.33% (▲534bps) - Board recommended a Final Dividend of ₹1.50 per Equity Share (15%) for the financial year 2025-26.

- The Board of Directors fixed August 06, 2026, as the date for the 34th Annual General Meeting. - Approved the Board of Directors' report, Corporate Governance report, and Management Discussion and Analysis Report for the 34th AGM. - Fixed book closure and Record Date for the payment of dividend for F.Y.2025-26.

- Trading window closed from July 01, 2026. - Reopens 48 hours after announcement of unaudited financial results for the quarter ended June 2026. - Applicable to designated persons, directors/KMP, and other designated employees.

- Board Meeting scheduled for July 04, 2026, at 12:15 PM. - Agenda includes fixing the 34th AGM date, approving various reports, and fixing the book closure/record date for F.Y. 2025-26 dividend payment.

- Standalone Operating Revenue for the quarter ended March 31, 2026 was ₹1,022.53 Lacs vs ₹723.20 Lacs in the prior year quarter (▲41.38% YoY) - Standalone EBITDA for the quarter ended March 31, 2026 was ₹139.81 Lacs vs ₹60.28 Lacs in the prior year quarter (▲131.95% YoY) - Standalone PAT for the quarter ended March 31, 2026 was ₹110.38 Lacs vs ₹61.04 Lacs in the prior year quarter (▲80.82% YoY) - Standalone EBITDA Margin expanded to 13.67% vs 8.33% in the prior year quarter (▲534 bps) - The Board recommended a Final Dividend of Rs. 1.50 per Equity Share (15%) for the financial year 2025-26. - Noted the formation of a new subsidiary, Oleo Biosciences Private Limited, in March 2026. - Approved an investment of up to ₹2.25 Crores in the subsidiary. - Reappointed three directors for a period of five years.

- Standalone Operating Revenue ₹10.23Cr vs ₹7.23Cr (▲41.39% YoY) - EBITDA ₹1.40Cr vs ₹0.60Cr (▲131.95% YoY) - PAT ₹1.10Cr vs ₹0.61Cr (▲80.82% YoY) - EBITDA Margin 13.67% vs 8.33% (▲534bps) - Board recommended a final dividend of ₹1.50 per equity share (15%) for FY 2025-26. - Noted the formation of a new subsidiary, Oleo Biosciences Private Limited, on March 31, 2026, with an approved investment of up to ₹2.25 Crores. - Approved the reappointment of Mr. Dipak Narendraprasad Patel, Mrs. Parul Dipak Patel, and Mrs. Tansi Nirmit Patel as directors for five-year terms.